Novel Physiologic Predictors of Positive Airway Pressure Effectiveness (NICEPAP) Study: Rationale, Design and Methods

Overview

Journal Sleep Breath

Publisher Springer

Date 2024 Jul 12

PMID 38995327

Authors

Andira I Anwar

Sean Byrne

Akanksha Sharma

Scott Sands

Andrew Wellman

Nancy S Redeker

Henry Yaggi

Andrey V Zinchuk

Affiliations

Soon will be listed here.

Abstract

Purpose: Continuous positive airway pressure (CPAP) is the primary therapy for obstructive sleep apnea (OSA); however the effectiveness of CPAP remains suboptimal. We describe the Novel PhysIologiC prEdictors of Positive Airway Pressure Effectiveness (NICEPAP) study. Its purpose is to determine whether physiological traits of OSA contribute to CPAP effectiveness.

Methods: NICEPAP (NCT05067088) is a prospective, observational cohort study conducted at an academic sleep center. Adults newly diagnosed with OSA (n = 267) are assessed for OSA traits of loop gain, arousal threshold, pharyngeal collapsibility, and muscle compensation from baseline polysomnography. We perform a comprehensive assessment of covariates relevant to CPAP adherence, efficacy, and patient-centered outcomes. Participants are followed for 12 months. Primary outcomes include (1) CPAP adherence (hours/night), (2) CPAP efficacy (apneas-hypopneas/hour), and (3) quality of life at six months measured by objective CPAP data and Functional Outcomes of Sleep Questionnaire. Secondary outcomes include sleep quality, sleepiness, insomnia, and neurocognitive function.

Results: Data on covariates, including demographics, sleep symptoms, medical history, medications, sleep quality, OSA and treatment self-efficacy, decisional balance, and socio-economic and social and partner support, are collected using validated instruments. The analysis for primary outcomes includes a generalized linear mixed model for an outcome (e.g., CPAP adherence) with OSA traits as exposures followed by the addition of relevant covariates.

Conclusion: The findings of the NICEPAP study will inform research aimed to enhance CPAP effectiveness. Understanding the role of physiological OSA traits in CPAP effectiveness is a crucial step toward a precision medicine approach to OSA.

References

Benjafield A, Ayas N, Eastwood P, Heinzer R, Ip M, Morrell M . Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019; 7(8):687-698. PMC: 7007763. DOI: 10.1016/S2213-2600(19)30198-5. View

Kendzerska T, Mollayeva T, Gershon A, Leung R, Hawker G, Tomlinson G . Untreated obstructive sleep apnea and the risk for serious long-term adverse outcomes: a systematic review. Sleep Med Rev. 2013; 18(1):49-59. DOI: 10.1016/j.smrv.2013.01.003. View

Mulgrew A, Al Lawati N, Ayas N, Fox N, Hamilton P, Cortes L . Residual sleep apnea on polysomnography after 3 months of CPAP therapy: clinical implications, predictors and patterns. Sleep Med. 2010; 11(2):119-25. DOI: 10.1016/j.sleep.2009.05.017. View

Crawford M, Espie C, Bartlett D, Grunstein R . Integrating psychology and medicine in CPAP adherence--new concepts?. Sleep Med Rev. 2013; 18(2):123-39. DOI: 10.1016/j.smrv.2013.03.002. View

Bakker J, Wang R, Weng J, Aloia M, Toth C, Morrical M . Motivational Enhancement for Increasing Adherence to CPAP: A Randomized Controlled Trial. Chest. 2016; 150(2):337-45. PMC: 4980541. DOI: 10.1016/j.chest.2016.03.019. View

Parthasarathy S, Wendel C, Haynes P, Atwood C, Kuna S . A pilot study of CPAP adherence promotion by peer buddies with sleep apnea. J Clin Sleep Med. 2013; 9(6):543-50. PMC: 3659373. DOI: 10.5664/jcsm.2744. View

Bakker J, Weaver T, Parthasarathy S, Aloia M . Adherence to CPAP: What Should We Be Aiming For, and How Can We Get There?. Chest. 2019; 155(6):1272-1287. DOI: 10.1016/j.chest.2019.01.012. View

Patil S, Ayappa I, Caples S, Kimoff R, Patel S, Harrod C . Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. J Clin Sleep Med. 2019; 15(2):301-334. PMC: 6374080. DOI: 10.5664/jcsm.7638. View

Owens R, Edwards B, Eckert D, Jordan A, Sands S, Malhotra A . An Integrative Model of Physiological Traits Can be Used to Predict Obstructive Sleep Apnea and Response to Non Positive Airway Pressure Therapy. Sleep. 2014; 38(6):961-70. PMC: 4434563. DOI: 10.5665/sleep.4750. View

10.

Eckert D, White D, Jordan A, Malhotra A, Wellman A . Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. Am J Respir Crit Care Med. 2013; 188(8):996-1004. PMC: 3826282. DOI: 10.1164/rccm.201303-0448OC. View

11.

Zinchuk A, Redeker N, Chu J, Liang J, Stepnowsky C, Brandt C . Physiological Traits and Adherence to Obstructive Sleep Apnea Treatment in Patients with Stroke. Am J Respir Crit Care Med. 2020; 201(12):1568-1572. PMC: 7301748. DOI: 10.1164/rccm.201911-2203LE. View

12.

Zinchuk A, Chu J, Liang J, Celik Y, Op de Beeck S, Redeker N . Physiological Traits and Adherence to Sleep Apnea Therapy in Individuals with Coronary Artery Disease. Am J Respir Crit Care Med. 2021; 204(6):703-712. PMC: 8521693. DOI: 10.1164/rccm.202101-0055OC. View

13.

Cheng W, Finnsson E, Agustsson J, Sands S, Hang L . Continuous positive airway pressure and adherence in patients with different endotypes of obstructive sleep apnea. J Sleep Res. 2023; 33(1):e13999. PMC: 10788376. DOI: 10.1111/jsr.13999. View

14.

Stanchina M, Robinson K, Corrao W, Donat W, Sands S, Malhotra A . Clinical Use of Loop Gain Measures to Determine Continuous Positive Airway Pressure Efficacy in Patients with Complex Sleep Apnea. A Pilot Study. Ann Am Thorac Soc. 2015; 12(9):1351-7. PMC: 5467091. DOI: 10.1513/AnnalsATS.201410-469BC. View

15.

Lettieri C, Shah A, Holley A, Kelly W, Chang A, Roop S . Effects of a short course of eszopiclone on continuous positive airway pressure adherence: a randomized trial. Ann Intern Med. 2009; 151(10):696-702. DOI: 10.7326/0003-4819-151-10-200911170-00006. View

16.

Edwards B, Sands S, Eckert D, White D, Butler J, Owens R . Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnoea. J Physiol. 2012; 590(5):1199-211. PMC: 3381825. DOI: 10.1113/jphysiol.2011.223925. View

17.

Schmickl C, Landry S, Orr J, Chin K, Murase K, Verbraecken J . Acetazolamide for OSA and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis. Chest. 2020; 158(6):2632-2645. PMC: 7768933. DOI: 10.1016/j.chest.2020.06.078. View

18.

Ni Y, Holzer R, Thomas R . Acute and long-term effects of acetazolamide in presumed high loop gain sleep apnea. Sleep Med. 2023; 107:137-148. DOI: 10.1016/j.sleep.2023.04.010. View

19.

Gray E, McKenzie D, Eckert D . Obstructive Sleep Apnea without Obesity Is Common and Difficult to Treat: Evidence for a Distinct Pathophysiological Phenotype. J Clin Sleep Med. 2016; 13(1):81-88. PMC: 5181619. DOI: 10.5664/jcsm.6394. View

20.

Sands S, Collet J, Gell L, Calianese N, Hess L, Vena D . Combination pharmacological therapy targeting multiple mechanisms of sleep apnoea: a randomised controlled cross-over trial. Thorax. 2024; 79(3):259-268. DOI: 10.1136/thorax-2023-220184. View